A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

This phase II study evaluated the efficacy and safety of AMG 102 (rilotumumab), a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in patients with recurrent glioblastoma (GBM). Patients with histologically confirmed, measurable recurrent GBM or gliosarcoma (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wen, Patrick Y., Schiff, David, Cloughesy, Timothy F., Raizer, Jeffrey J., Laterra, John, Smitt, Melanie, Wolf, Michael, Oliner, Kelly S., Anderson, Abraham, Zhu, Min, Loh, Elwyn, Reardon, David A.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2011
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3064694/
https://ncbi.nlm.nih.gov/pubmed/21297127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq198
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars